{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:51:07Z","timestamp":1790639467225,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01DE026941"],"award-info":[{"award-number":["R01DE026941"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Most cancer patients diagnosed with late-stage head and neck squamous cell carcinoma are treated with chemoradiotherapy, which can lead to toxicity. One potential alternative is tumor-limited conversion of a prodrug into its cytotoxic form. We reason this could be achieved by transient and tumor-specific expression of purine nucleoside phosphorylase (PNP), an <jats:italic>Escherichia coli<\/jats:italic> enzyme that converts fludarabine into 2-fluoroadenine, a potent cytotoxic drug. To efficiently express bacterial PNP in tumors, we evaluate 44 chemically distinct lipid nanoparticles (LNPs) using species-agnostic DNA barcoding in tumor-bearing mice. Our lead LNP, designated LNP intratumoral (LNP<jats:sup>IT<\/jats:sup>), delivers mRNA that leads to PNP expression in vivo. Additionally, in tumor cells transfected with LNP<jats:sup>IT<\/jats:sup>, we observe upregulated pathways related to RNA and protein metabolism, providing insight into the tumor cell response to LNPs in vivo. When mice are treated with LNP<jats:sup>IT<\/jats:sup>-PNP, then subsequently given fludarabine phosphate, we observe anti-tumor responses. These data are consistent with an approach in which LNP-mRNA expression of a bacterial enzyme activates a prodrug in solid tumors.<\/jats:p>","DOI":"10.1038\/s41467-025-58548-1","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T20:43:30Z","timestamp":1744490610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2859-3074","authenticated-orcid":false,"given":"Sebastian G.","family":"Huayamares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0293-4694","authenticated-orcid":false,"given":"Regina","family":"Rab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9894-3821","authenticated-orcid":false,"given":"Yuning","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsane","family":"Radmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-2733","authenticated-orcid":false,"given":"Hyejin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zenhausern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagelu R.","family":"Achyut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1960-8302","authenticated-orcid":false,"given":"Melissa","family":"Gilbert Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa P.","family":"Lokugamage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Loughrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4094-2054","authenticated-orcid":false,"given":"Elisa Schrader","family":"Echeverri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7476-5406","authenticated-orcid":false,"given":"Alejandro J.","family":"Da Silva Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Shajii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Tiegreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-3354","authenticated-orcid":false,"given":"Eric J.","family":"Sorscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7580-436X","authenticated-orcid":false,"given":"James E.","family":"Dahlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"58548_CR1","doi-asserted-by":"crossref","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2020).","DOI":"10.1056\/NEJMoa2035389"},{"key":"58548_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"58548_CR3","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1200\/JCO.2020.38.15_suppl.3092","volume":"38","author":"MR Patel","year":"2020","unstructured":"Patel, M. R. et al. A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral (iTu) injection alone and in combination with durvalumab. J. Clin. Oncol. 38, 3092 (2020).","journal-title":"J. Clin. Oncol."},{"key":"58548_CR4","unstructured":"Moderna in Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies - NCT03739931 (https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03739931?term=NCT03739931&draw=2&rank=1; 2018)."},{"key":"58548_CR5","doi-asserted-by":"crossref","unstructured":"Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E. & Sorscher, E. J. Nucleic acid-based drugs for patients with solid tumours. Nat. Rev. Clin. Oncol. 21, 407\u2013427 (2024).","DOI":"10.1038\/s41571-024-00883-1"},{"key":"58548_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","volume":"345","author":"J-Q Liu","year":"2022","unstructured":"Liu, J.-Q. et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J. Control. Rel. 345, 306\u2013313 (2022).","journal-title":"J. Control. Rel."},{"key":"58548_CR7","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/s43018-020-0095-6","volume":"1","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nat. Cancer 1, 882\u2013893 (2020).","journal-title":"Nat. Cancer"},{"key":"58548_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.omtn.2022.09.010","volume":"30","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy. Mol. Ther. Nucleic Acids 30, 184\u2013197 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"58548_CR9","doi-asserted-by":"crossref","unstructured":"Rosenblum, D. et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci. Adv. 6, eabc9450 (2020).","DOI":"10.1126\/sciadv.abc9450"},{"key":"58548_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Prim. 6, 92 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"58548_CR11","doi-asserted-by":"crossref","unstructured":"Barsouk, A., Aluru, J. S., Rawla, P., Saginala, K. & Barsouk, A. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med. Sci. 11, 42 (2023).","DOI":"10.3390\/medsci11020042"},{"key":"58548_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ijc.20740","volume":"114","author":"AL Carvalho","year":"2005","unstructured":"Carvalho, A. L., Nishimoto, I. N., Califano, J. A. & Kowalski, L. P. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J. Cancer 114, 806\u2013816 (2005).","journal-title":"Int J. Cancer"},{"key":"58548_CR13","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/hed.25627","volume":"41","author":"TE Behbahani","year":"2019","unstructured":"Behbahani, T. E., Rosenthal, E. L., Parker, W. B. & Sorscher, E. J. Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck. Head. Neck 41, 1979\u20131983 (2019).","journal-title":"Head. Neck"},{"key":"58548_CR14","doi-asserted-by":"crossref","unstructured":"Elgemeie, G. H. & Mohamed-Ezzat, R. A. In New Strategies Targeting Cancer Metabolism. (eds. Elgemeie G. H. & Mohamed-Ezzat R. A.) 69\u2013105 (Elsevier, 2022).","DOI":"10.1016\/B978-0-12-821783-2.00005-4"},{"key":"58548_CR15","doi-asserted-by":"crossref","unstructured":"Parker, W. B. & Sorscher, E. J. Use of E. coli purine nucleoside phosphorylase in the treatment of solid tumors. Curr. Pharm. Des. 23, 7003-7024 (2017).","DOI":"10.2174\/1381612823666171109101851"},{"key":"58548_CR16","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/annonc\/mdv196","volume":"26","author":"EL Rosenthal","year":"2015","unstructured":"Rosenthal, E. L. et al. Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors. Ann. Oncol. 26, 1481\u20131487 (2015).","journal-title":"Ann. Oncol."},{"key":"58548_CR17","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.4161\/hv.29594","volume":"10","author":"H Fausther-Bovendo","year":"2014","unstructured":"Fausther-Bovendo, H. & Kobinger, G. P. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what\u2019s important? Hum. Vaccin Immunother. 10, 2875\u20132884 (2014).","journal-title":"Hum. Vaccin Immunother."},{"key":"58548_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/156652311796150372","volume":"11","author":"YS Ahi","year":"2011","unstructured":"Ahi, Y. S., Bangari, D. S. & Mittal, S. K. Adenoviral vector immunity: its implications and circumvention strategies. Curr. Gene Ther. 11, 307\u2013320 (2011).","journal-title":"Curr. Gene Ther."},{"key":"58548_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41565-021-01030-y","volume":"17","author":"MZC Hatit","year":"2022","unstructured":"Hatit, M. Z. C. et al. Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles. Nat. Nanotechnol. 17, 310\u2013318 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"58548_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.anl.2017.07.011","volume":"45","author":"KJ Cho","year":"2018","unstructured":"Cho, K. J., Park, E. J., Kim, M. S. & Joo, Y. H. Characterization of FaDu-R, a radioresistant head and neck cancer cell line, and cancer stem cells. Auris Nasus Larynx 45, 566\u2013573 (2018).","journal-title":"Auris Nasus Larynx"},{"key":"58548_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00280-019-04018-7","volume":"85","author":"WB Parker","year":"2020","unstructured":"Parker, W. B. et al. The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors. Cancer Chemother. Pharm. 85, 573\u2013583 (2020).","journal-title":"Cancer Chemother. Pharm."},{"key":"58548_CR22","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1021\/acs.nanolett.8b00432","volume":"18","author":"K Paunovska","year":"2018","unstructured":"Paunovska, K. et al. A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation. Nano Lett. 18, 2148\u20132157 (2018).","journal-title":"Nano Lett."},{"key":"58548_CR23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357\u20131364 (2010).","journal-title":"Mol. Ther."},{"key":"58548_CR24","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int Ed. Engl. 51, 8529\u20138533 (2012).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"58548_CR25","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1073\/pnas.1322937111","volume":"111","author":"Y Dong","year":"2014","unstructured":"Dong, Y. et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. 111, 3955\u20133960 (2014).","journal-title":"Proc. Natl Acad. Sci."},{"key":"58548_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int. J. Pharm. 601, 120586 (2021).","journal-title":"Int. J. Pharm."},{"key":"58548_CR27","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1073\/pnas.0910603106","volume":"107","author":"KT Love","year":"2010","unstructured":"Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. 107, 1864\u20131869 (2010).","journal-title":"Proc. Natl Acad. Sci."},{"key":"58548_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jconrel.2022.11.037","volume":"353","author":"AJ Da Silva Sanchez","year":"2023","unstructured":"Da Silva Sanchez, A. J. et al. Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery. J. Control. Release 353, 270\u2013277 (2023).","journal-title":"J. Control. Release"},{"key":"58548_CR29","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jconrel.2023.04.005","volume":"357","author":"SG Huayamares","year":"2023","unstructured":"Huayamares, S. G. et al. High-throughput screens identify a lipid nanoparticle that preferentially delivers mRNA to human tumors in vivo. J. Control. Release 357, 394\u2013403 (2023).","journal-title":"J. Control. Release"},{"key":"58548_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14527-2","volume":"11","author":"S Patel","year":"2020","unstructured":"Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).","journal-title":"Nat. Commun."},{"key":"58548_CR31","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1021\/acs.nanolett.7b02664","volume":"17","author":"S Patel","year":"2017","unstructured":"Patel, S. et al. Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA. Nano Lett. 17, 5711\u20135718 (2017).","journal-title":"Nano Lett."},{"key":"58548_CR32","doi-asserted-by":"crossref","unstructured":"Paunovska, K. et al. Nanoparticles containing oxidized cholesterol deliver mRNA to the liver microenvironment at clinically relevant doses. Adv. Mater. (Deerfield Beach, Fla.), e1807748 (2019).","DOI":"10.1002\/adma.201807748"},{"key":"58548_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.omtn.2017.11.005","volume":"10","author":"KJ Kauffman","year":"2018","unstructured":"Kauffman, K. J. et al. Rapid, single-cell analysis and discovery of vectored mRNA transfection in vivo with a loxP-flanked tdTomato reporter mouse. Mol. Ther. Nucleic Acids 10, 55\u201363 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"58548_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"58548_CR35","doi-asserted-by":"crossref","unstructured":"LoPresti, S. T., Arral, M. L., Chaudhary, N. & Whitehead, K. A. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilities targeted mRNA delivery to the spleen and lungs. J. Control. Rel. 345, 819-831 (2022).","DOI":"10.1016\/j.jconrel.2022.03.046"},{"key":"58548_CR36","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1021\/acs.nanolett.2c04479","volume":"23","author":"A Radmand","year":"2023","unstructured":"Radmand, A. et al. The transcriptional response to lung-targeting lipid nanoparticles in vivo. Nano Lett. 23, 993\u20131002 (2023).","journal-title":"Nano Lett."},{"key":"58548_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06508-3","volume":"9","author":"PM Tiwari","year":"2018","unstructured":"Tiwari, P. M. et al. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat. Commun. 9, 3999 (2018).","journal-title":"Nat. Commun."},{"key":"58548_CR38","doi-asserted-by":"crossref","unstructured":"Sago, C. D. et al. Modifying a commonly expressed endocytic receptor retargets nanoparticles in Vivo. Nano Lett. 18, 7590-7600 (2018).","DOI":"10.1021\/acs.nanolett.8b03149"},{"key":"58548_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.28","volume":"1","author":"NM Belliveau","year":"2012","unstructured":"Belliveau, N. M. et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol. Ther. Nucleic Acids 1, e37 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"58548_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cobme.2018.08.001","volume":"7","author":"MP Lokugamage","year":"2018","unstructured":"Lokugamage, M. P., Sago, C. D. & Dahlman, J. E. Testing thousands of nanoparticles in vivo using DNA barcodes. Curr. Opin. Biomed. Eng. 7, 1\u20138 (2018).","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"58548_CR41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307801120","volume":"121","author":"A Radmand","year":"2024","unstructured":"Radmand, A. et al. Cationic cholesterol-dependent LNP delivery to lung stem cells, the liver, and heart. Proc. Natl Acad. Sci. 121, e2307801120 (2024).","journal-title":"Proc. Natl Acad. Sci."},{"key":"58548_CR42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.31557\/APJCP.2021.22.4.1069","volume":"22","author":"J Panaampon","year":"2021","unstructured":"Panaampon, J., Sasamoto, K., Kariya, R. & Okada, S. Establishment of nude mice lacking NK cells and their application for human tumor Xenografts. Asian Pac. J. Cancer Prev. 22, 1069\u20131074 (2021).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"58548_CR43","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.xphs.2020.06.009","volume":"109","author":"MM Pressnall","year":"2020","unstructured":"Pressnall, M. M., Huayamares, S. G. & Berkland, C. J. Immunostimulant complexed with polylysine limits transport and maintains immune cell activation. J. Pharm. Sci. 109, 2836\u20132846 (2020).","journal-title":"J. Pharm. Sci."},{"key":"58548_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120812","volume":"605","author":"MM Pressnall","year":"2021","unstructured":"Pressnall, M. M. et al. Glatiramer acetate enhances tumor retention and innate activation of immunostimulants. Int. J. Pharm. 605, 120812 (2021).","journal-title":"Int. J. Pharm."},{"key":"58548_CR45","doi-asserted-by":"crossref","unstructured":"Hatit, M. Z. C. et al. Nanoparticle stereochemistry-dependent endocytic processing improves in vivo mRNA delivery. Nat. Chem. 15, 508-515 (2023).","DOI":"10.1038\/s41557-023-01138-9"},{"key":"58548_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36691-x","volume":"14","author":"J-H Choi","year":"2023","unstructured":"Choi, J.-H. et al. Single-cell transcriptome profiling of the stepwise progression of head and neck cancer. Nat. Commun. 14, 1055 (2023).","journal-title":"Nat. Commun."},{"key":"58548_CR47","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nmeth.4380","volume":"14","author":"M Stoeckius","year":"2017","unstructured":"Stoeckius, M. et al. Simultaneous epitope and transcriptome measurement in single cells. Nat. Methods 14, 865\u2013868 (2017).","journal-title":"Nat. Methods"},{"key":"58548_CR48","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.3390\/curroncol28040241","volume":"28","author":"K Sharaf","year":"2021","unstructured":"Sharaf, K. et al. Discrimination of cancer stem cell markers ALDH1A1, BCL11B, BMI-1, and CD44 in different tissues of HNSCC patients. Curr. Oncol. 28, 2763\u20132774 (2021).","journal-title":"Curr. Oncol."},{"key":"58548_CR49","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00405-023-08213-4","volume":"281","author":"Z Wu","year":"2024","unstructured":"Wu, Z. et al. SLA2 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment. Eur. Arch. Otorhinolaryngol. 281, 427\u2013440 (2024).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"58548_CR50","doi-asserted-by":"crossref","unstructured":"You, G. R. et al. MYH9 Facilitates cell invasion and radioresistance in head and neck cancer via modulation of cellular ROS levels by activating the MAPK-Nrf2-GCLC Pathway. Cells 11, 2855 (2022).","DOI":"10.3390\/cells11182855"},{"key":"58548_CR51","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/odi.13910","volume":"29","author":"MK Lee","year":"2023","unstructured":"Lee, M. K., Zhang, X., Kim, H. J. & Hwang, Y. S. Peroxiredoxin 5 is involved in cancer cell invasion and tumor growth of oral squamous cell carcinoma. Oral. Dis. 29, 423\u2013435 (2023).","journal-title":"Oral. Dis."},{"key":"58548_CR52","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1074\/mcp.TIR120.002155","volume":"19","author":"J Griss","year":"2020","unstructured":"Griss, J. et al. ReactomeGSA - Efficient multi-omics comparative pathway analysis. Mol. Cell Proteom. 19, 2115\u20132125 (2020).","journal-title":"Mol. Cell Proteom."},{"key":"58548_CR53","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/sj.gt.3301286","volume":"7","author":"VK Gadi","year":"2000","unstructured":"Gadi, V. K. et al. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther. 7, 1738\u20131743 (2000).","journal-title":"Gene Ther."},{"key":"58548_CR54","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/0194599812442037","volume":"147","author":"NP Judd","year":"2012","unstructured":"Judd, N. P., Allen, C. T., Winkler, A. E. & Uppaluri, R. Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. Otolaryngol. Head. Neck Surg. 147, 493\u2013500 (2012).","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"58548_CR55","unstructured":"Hoffman, R. M. In Reference Module in Life Sciences (Elsevier, 2017)."},{"key":"58548_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"58548_CR57","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for Transthyretin Amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"58548_CR58","unstructured":"Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting. https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-therapeutics-presents-new-interim-data-first-human (2022)."},{"key":"58548_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1021\/acs.accounts.1c00601","volume":"55","author":"D Loughrey","year":"2022","unstructured":"Loughrey, D. & Dahlman, J. E. Non-liver mRNA delivery. Acc. Chem. Res. 55, 13\u201323 (2022).","journal-title":"Acc. Chem. Res."},{"key":"58548_CR60","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","volume":"5","author":"MP Lokugamage","year":"2021","unstructured":"Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059\u20131068 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"58548_CR61","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1073\/pnas.1200718109","volume":"109","author":"JE Zuckerman","year":"2012","unstructured":"Zuckerman, J. E., Choi, C. H. J., Han, H. & Davis, M. E. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc. Natl Acad. Sci. USA 109, 3137\u20133142 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"58548_CR62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jconrel.2020.06.029","volume":"326","author":"A Huang","year":"2020","unstructured":"Huang, A. et al. Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials. J. Control. Release 326, 203\u2013221 (2020).","journal-title":"J. Control. Release"},{"key":"58548_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202000251","volume":"20","author":"SG Huayamares","year":"2020","unstructured":"Huayamares, S. G. et al. Constructing a biomaterial to simulate extracellular drug transport in solid tumors. Macromol. Biosci. 20, 2000251 (2020).","journal-title":"Macromol. Biosci."},{"key":"58548_CR64","doi-asserted-by":"publisher","first-page":"100200","DOI":"10.1016\/j.crbiot.2024.100200","volume":"7","author":"SG Huayamares","year":"2024","unstructured":"Huayamares, S. G., Zenhausern, R. & Loughrey, D. Nanocarriers for inhaled delivery of RNA therapeutics. Curr. Res. Biotechnol. 7, 100200 (2024).","journal-title":"Curr. Res. Biotechnol."},{"key":"58548_CR65","unstructured":"BioNTech in A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT) - NCT04534205 (https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04534205?term=NCT04534205&draw=2&rank=1; 2020)."},{"key":"58548_CR66","unstructured":"NCT03754933: Safety and Efficacy of Repeat Administration of Ad\/PNP and Fludarabine Phosphate in Patients With Local Head\/Neck Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03754933 (2018)."},{"key":"58548_CR67","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1021\/acsnano.1c10631","volume":"16","author":"JP Beyersdorf","year":"2022","unstructured":"Beyersdorf, J. P. et al. Robust, durable gene activation in vivo via mRNA-encoded activators. ACS Nano 16, 5660\u20135671 (2022).","journal-title":"ACS Nano"},{"key":"58548_CR68","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","volume":"39","author":"EL Blanchard","year":"2021","unstructured":"Blanchard, E. L. et al. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents. Nat. Biotechnol. 39, 717\u2013726 (2021).","journal-title":"Nat. Biotechnol."},{"key":"58548_CR69","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ymthe.2020.01.002","volume":"28","author":"KE Lindsay","year":"2020","unstructured":"Lindsay, K. E. et al. Aerosol delivery of synthetic mRNA to vaginal mucosa leads to durable expression of broadly neutralizing antibodies against HIV. Mol. Ther.: J. Am. Soc. Gene Ther. 28, 805\u2013819 (2020).","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"58548_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32281-5","volume":"13","author":"H Ni","year":"2022","unstructured":"Ni, H. et al. Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo. Nat. Commun. 13, 4766 (2022).","journal-title":"Nat. Commun."},{"key":"58548_CR71","unstructured":"Benjamin, K., Dinar, Y. & Alexander, D. STARsolo: accurate, fast and versatile mapping\/quantification of single-cell and single-nucleus RNA-seq data. bioRxiv, 2021.2005.2005.442755 (2021)."},{"key":"58548_CR72","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e3529 (2021).","journal-title":"Cell"},{"key":"58548_CR73","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: Doublet detection in single-cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst. 8, 329\u2013337.e324 (2019).","journal-title":"Cell Syst."},{"key":"58548_CR74","unstructured":"Tri, L. et al. BBrowser: Making single-cell data easily accessible. bioRxiv, 2020.2012.2011.414136 (2020)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58548-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:05:45Z","timestamp":1744506345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58548-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58548"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58548-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"31 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.G.H., R.R., B.R.A., M.P.L., P.J.S., E.S. and J.E.D. have filed intellectual property related to this manuscript (PCT\/US2023\/033245). J.E.D. is an advisor to Readout Capital, Edge Animal Health, and Nava Therapeutics. E.J.S. has an ownership interest in PNP Therapeutics, Inc., and serves on the Board of Directors for the company, which develops products used in cancer research. Dr. Sorscher is also an inventor of technology being evaluated in studies described by this report. The terms of this arrangement for Dr. Sorscher have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3490"}}